Kusajili – Centralise les essais cliniques mondiaux

Résultat de votre recherche par promoteur : Bayer AB, Bayer Schering Pharma

Femme Max 99 ans
Bayer AB, Bayer Schering Pharma MAJ Il y a 4 ans

A double-blind, randomized, multi-center study to investigate the endometrial safety of a continuous, combined, oral estrogen/progestin preparation (0.5 mg 17b-estradiol [E2] / 0.25 mg drospirenone [DRSP]) and to compare the bleeding pattern of subjects treated with 0.5 mg E2 / 0.25 mg DRSP with the bleeding pattern of subjects treated with 1.0 mg E2 / 0.5 mg norethisterone acetate (NETA) when used for hormone therapy (HT) for 1 year in post-menopausal women The main objective is to investigate the endometrial safety of a continuous, combined, oral estrogen/progestin preparation.

Pays Aucun
Organes Aucun
Spécialités Aucune

Essai clos aux inclusions

Plus d'informations